Incyte names Jacqualyn “Jackie” A. Fouse to its board of directors
Incyte announced the appointment of Jacqualyn “Jackie” A. Fouse, Ph.D., as a new member of the Board of Directors, effective November 14, 2017.
“We are pleased to welcome Jackie to Incyte. Her impressive background will further strengthen and add to the experience of our Board and leadership team,” stated Hervé Hoppenot, Incyte’s Chairman and Chief Executive Officer. “We look forward to benefiting from her counsel as we continue to build Incyte into a global biopharmaceutical company.”
“I am excited to join Incyte at such an important time in its evolution. The Company’s commitment to scientific excellence has positively impacted the lives of thousands of patients treated with Jakafi, and simultaneously produced a development pipeline of product candidates that is much-admired in the biopharma space,” stated Dr. Fouse. “I look forward to working closely with the rest of the team to advance Incyte and its science as we aim to continue helping patients in need.”
Dr. Fouse is currently the Executive Chair of Dermavant Sciences, a position she has held since July 2017. Prior to joining Dermavant, Dr. Fouse served in various senior capacities at Celgene Corporation, most recently as Strategic Advisor to the Management Executive Committee. Her previous roles at Celgene included President and Chief Operating Officer; President, Hematology and Oncology; and Chief Financial Officer. Prior to joining Celgene, Dr. Fouse served as Chief Financial Officer of Bunge Limited, and was previously Chief Financial Officer and Head of Corporate Strategy at Alcon Laboratories, Inc. Dr. Fouse currently serves as a Director of Dick’s Sporting Goods, Inc.
Dr. Fouse earned her B.A. and M.A. in Economics and a Ph.D. in Finance from the University of Texas at Arlington.